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Airway epithelial cells (AECs) are part of the frontline defense against infection of pathogens by providing both a physical
barrier and immunological function. The role of AECs in the innate and adaptive immune responses, through the production
of antimicrobial molecules and proinﬂammatory factors against a variety of pathogens, has been well established. Tuberculosis
(TB), a contagious disease primarily aﬀecting the lungs, is caused by the infection of various strains of mycobacteria. In response
to mycobacteria infection, epithelial expression of Toll-like receptors and surfactant proteins plays the most prominent roles in the
recognition and binding of the pathogen, as well as the initiation of the immune response. Moreover, the antimicrobial substances,
proinﬂammatory factors secreted by AECs, composed a major part of the innate immune response and mediation of adaptive
immunity against the pathogen. Thus, a better understanding of the role and mechanism of AECs in response to mycobacteria will
provide insight into the relationship of epithelial cells and lung immunocytes against TB, which may facilitate our understanding
of the pathogenesis and immunological mechanism of pulmonary tuberculosis disease.
1.Introduction
The lung is an organ lined by numerous distinct types of
epithelial cells in diﬀerent anatomical regions. Pulmonary
epithelium was initially thought of as a complicated phys-
ical barrier to block potentially harmful inhaled bacilli
and substances from tissue invasion. However, increasing
evidence has demonstrated that epithelial cells also play
critical functions in initiating and expanding airway host
defense mechanisms in the lung and providing the initial
defense against inhaled microorganisms. Furthermore, these
epithelial cells are capable of not only regulating innate
immunity but also producing functional molecules that
physically interacted with immunocytes to activate adaptive
immunity [1, 2]. These epithelial cell-derived antimicrobial
moleculesand/orpeptidesweremultifunctionalagentscapa-
ble of linking the innate and adaptive immune responses
[3]. In response to invasion of pathogens, airway epithelial
cells (AECs) secrete various microorganism killing eﬀectors,
such as mucins antimicrobial peptides (AMPs) and reactive
oxygen species (ROS), into the airway lumen to control
the composition of airway surface liquid (ASL). These cells
also produce proinﬂammatory cytokines, growth factors,
and chemokines that recruit and activate phagocytes to
the site of infection eliminating pathogens by phagocytosis.
These eﬀectors play key roles in innate immunity of the
airway against microorganism invasion and pathogenesis
of pulmonary inﬂammatory diseases caused by chronic
bacterial infection [4].
Mycobacterium tuberculosis (Mtb) is an extremely dan-
gerous pathogen that primarily infects the lung and is known
for its capability to escape innate immune eﬀector cells
(such as macrophages and airway epithelial cells) causing
tuberculosis in humans and animals [5]. The AECs are one
of the ﬁrst host cells encountering invaded mycobacterial
pathogens, despite increasing evidence, which demonstrates
the potential roles of these cells in the tuberculosis (TB)
pathogenesis, as well as the innate and adaptive immune
responses against the infection [6–9]. The exact mechanism
of epithelial mediated host defense and the clinical relevance2 Clinical and Developmental Immunology
of the epithelial cell-mediated immune responses remain
poorlyunderstood.Thispaperfocusesoncurrentknowledge
regarding the roles of AECs in response to mycobacteria
infection.Anemphasiswasplacedontherecentlyrecognized
functions of epithelial cells in innate and adaptive immunity
against mycobacteria, particularly the pathogen recognition
and host defense of AECs to Mtb.
2. AirwayEpithelialCellsand Pathogen
Recognition of Mycobacteria
Mycobacterium utilizes multiple strategies for establishing
infection of the lung, including adhering, invasion, and
replicationinalveolarmacrophages[6,10,11].Animportant
step of infection is the initial contact of a pathogen to
host cells including epithelial cells. The innate immune
response is the ﬁrst line of host defense responsible for
immediate recognition and control of pathogen invasion.
The lung microenvironment contains an intricate milieu
of pattern recognition molecules in the innate immune
system that contribute to the host primary response to
inhaled pathogens such as Mtb. It has been suggested that
Mtb aﬀects the result of the bacillus-host interaction with
various recognition molecules [12, 13]. The family of Toll-
like receptors (TLRs) and surfactant proteins (SPs) of AECs
playakeyroleintherecognitionandbindingofthepathogen
to epithelial cells during Mtb infection. Additionally, other
patternrecognition receptors(PRRs)suchasNOD2,Dectin-
1,c-typelectinreceptors(CLPs),mannosereceptor,andDC-
SIGN are also believed to be involved in the recognition of
Mtb [14].
2.1. Role of Epithelial TLRs in the Recognition of Mycobac-
teria. Genetic association studies revealed that TLR vari-
ants contributed to the susceptibility of humans to TB
[15] .T h eg e n e so fv a r i o u sT L R sh a v eb e e nd e m o n s t r a t e d
to be predominantly expressed in immunocyte such as
macrophages, dendritic cells (DCs), B lymphocytes, mono-
cytes, and natural killer (NK) cells. The AECs have also been
shown to constitutively express TLRs which are one of the
most important PRRs for pathogen recognition. These TLRs
mediate the host-pathogen interaction through pathogen-
associated molecular patterns (PAMPs) and initiate appro-
priate signaling before immune cells are recruited to the
airways. To date, thirteen distinct mammalian TLRs have
been discovered, ten of which recognize PAMPs, and have
been identiﬁed in humans (designated TLR-1 to 10). The
expression of TLR-1, TLR-2, TLR-4, TLR-5, TLR-6, and
TLR10 was located at the apical cell membrane of AECs
where they mainly recognize proteins, lipoproteins, and the
polysaccharides of the bacteria. In addition, the expression
of TLR-3, TLR-7, TLR-8, and TLR-9 was detected in cyto-
plasmic compartments where they scavenge diﬀerent types
of nucleic acids from viruses [16–18]. Each TLR recognizes a
unique molecular pattern and a variety of ligands to mediate
the production of the appropriate cytokines to produce an
eﬀective immune response.
In response to the infection of Mtb, airway epithelial
activationofNF-κBandotherassociatedsignalingmolecules
are activated via TLR-mediated signaling pathways. Previous
studies have demonstrated functional TLR-1-6 and TLR-9
expressedinhumanbronchialepithelialcells[13]andseveral
TLRs involved in the immune response of AECs against Mtb
infection (Table 1). Furthermore, human bronchial epithe-
lium was capable of regulating its sensitivity to recognize
microbes by management of the TLR’s expression levels
to control microbial recognition in mucosal compartments
[13]. Mice deﬁcient of myeloid diﬀerentiation factor 88
(MyD88), a TLR mediator molecule, were approximately
twofold more susceptible to lethal doses of Mtb infection
relative to wild-type mice even though MyD88-deﬁcient
mice vaccinated with Mycobacterium bovis Bacille Calmette-
Gu´ erin (BCG) were able to confer substantial protection
from acute Mtb infection [19]. This study suggests that
MyD88-dependent TLR signaling might be dispensable to
adaptiveimmuneresponsestoMtb,butcrucialfortheinnate
immune response to control Mtb infection. Among these,
TLRs, TLR-2, TLR-4, TLR-6, and MyD88 played the most
prominent roles in the initiation of the immune response
against Mtb [20].
TLR-2isexpressedthroughoutthehumanairwayepithe-
lium, predominantly in the noncolumnar epithelial and
alveolar cells [21], which mediated responses to a variety
of bacterial components including the lipoproteins of Mtb,
Gram-positive and Gram-negative bacteria [22]. In response
to Mtb infection, TLR-2 was speciﬁcally targeted to a 19kDa
lipoprotein and lipoarabinomannan of this pathogen, and its
activity,ligandspeciﬁcity,andcapacityofsignaltransduction
were mainly determined by a heterodimer formed with TLR-
2 and other TLR family members, such as TLR-1 and TLR-
6[ 23]. It has been suggested that the formation of a TLR-
2 heterodimer with TLR-1 or TLR-6 has evolved to expand
the ligand spectrum to promote the innate immune system
for recognition of numerous structures of lipoproteins and
lipopeptides presented by diﬀerent pathogens [24–26]. TLR-
2-deﬁcient mice infected with live mycobacterial aerosol
displayed reduced bacterial clearance, a defective granulo-
matous response, and development of chronic pneumonia.
The pulmonary immune responses in TLR-2-deﬁcient mice
showed increased levels of IFN-γ,T N F - α, and IL-12p40, as
well as the CD4+ and CD8+ cell fractions. However, these
responses were not suﬃcient enough to protect the deﬁcient
mice from Mtb infection within 5 months after infection
suggesting that TLR-2 might be a regulator of inﬂammation,
and the exaggerated immune inﬂammatory response in
these mice resulting from the absence of TLR-2 [27]. In
AECs, TLR-2-dependent activation has been demonstrated
to function as an indirect role in host defense by inducing
the proinﬂammatory cytokine interleukin (IL) 8 (IL-8) and
the antimicrobial peptide human β-defensin-2 (HBD-2).
The action of HBD-2 was believed to act through the
chemokine receptor C-C chemokine receptor 6 (CCR6) to
recruit immature dendritic cells (DCs) and memory T cells
to the site of infection [28]. The neutrophil chemoattractant,
IL-8, recruits these cells to the site of pathogen exposure and
eventually eliminates the infection [29]. These processes mayClinical and Developmental Immunology 3
Table 1: Evidenced TLR-related AEC in response to Mtb infection.
TLRs Typical Ligands Cellular location References
TLR1 Microbial lipoproteins Cell membrane [93, 94]
TLR2 Microbial lipoproteins; PGN; LTA; zymosan; Cell membrane [21,22,24,25,27,94,95]
TLR3 dsRNA Intracellular components [95–97]
TLR4 LPS; RSV S protein; retroviral envelope protein Cell membrane [34]
TLR5 Flagellin Cell membrane [27, 33, 35, 98, 99]
TLR6 LTA; zymosan; diacyl lipopeptides Cell membrane [27, 93, 100]
TLR7 ssRNA imidazoquinoline Intracellular components [95, 101]
TLR8 ssRNA imidazoquinoline Intracellular components [101–103]
TLR9 Demethylated CpG DNA Intracellular components [60, 98, 101, 104]
LPS: lipopolysaccharide; ssRNA: single-stranded RNA; dsRNA: double-stranded RNA; LTA: lipoteichoic acid; PGN: peptidoglycan; RSV: respiratory syncytial
virus.
contribute to the resulting adaptive immune response at the
site of infection [30].
The function of TLR-4 in both the host’s innate and
adaptive immunities has been extensively studied, as well
as TLR-4 expressed in alveolar and bronchial epithelial
cells, and increased in the cells activated by TLR-4 ligands
[18, 31, 32]. However, it is diﬃcult to distinctly deﬁne
the exact role of TLR-4 against Mtb infection. TLR-4
mutant (C3H/HeJ) mice intranasally infected with live Mtb
were more susceptible to pathogen and development of
pulmonary tuberculosis relative to wild-type (C3H/HeN)
mice, suggesting that TLR-4 may play a protective role
in host defense against lung infection by Mtb [33]. This
result was consistent with the ﬁnding that TLR4 is crit-
ical in controlling chronic Mtb infection in mice [34].
However, a controversial report found that TLR-4-mutant
mice exhibited increased resistance to low doses of Mtb
infection relative to their wild-type litter mates in a dose-
dependentmanner[35].Furthermore,TLR-2/TLR-4/TLR-6-
deﬁcient mice showed their capacity to control chronic M.
bovis infection, indicating that TLR-2, TLR-4, and/or TLR-
6, may be redundant in controlling mycobacteria infection
[27]. Synergistic interactions of TLR-2, TLR-6 and TLR-9 in
AECs induced high levels of antimicrobial activity against
Pseudomonas aeruginosa infection in mice [36], suggesting
that multiple TLRs in AECs may produce innate immune
responses by the activation of EGFR via a cell signal cascade
[37]. These results demonstrate the complicated nature of
TLR signaling and hence warrant further studies to establish
its protective role against Mtb infection.
2.2. Other Pattern Recognition Receptors. Additional epithe-
lial PRRs have been investigated including Dectin-1, CLPs,
NOD2, DC-SIGN, and the mannose receptor. Dectin-1,
expressed on the surface of myeloid lineage cells, was
initially identiﬁed as fungal PRR that bound to β-glucans
and triggered cytokine production by facilitating interac-
tion with TLR-2 [38]. Recent studies that investigated the
innate response to mycobacteria demonstrated Dectin-1
expression in alveolar type 2 (ATII) cells that played a
critical role in response to Mtb in these non-phagocytic
cells [38–40]. A549 cells, an ATII cell line, infected with
Mtb resulted in active induction of Dectin-1 in a TLR-2-
dependent manner. Furthermore, the induction of Dectin-1
and Mtb-mediated production of ROS was mutually depen-
dent. Additionally, Mtb-dependent Dectin-1 expression was
also dependent upon Src kinases. Selective inhibition of
Src signaling dramatically decreased Dectin-1 expression.
Moreover, Mtb internalization could be partially blocked by
silencing Dectin-1 expression, inhibiting Src kinases, or pre-
treating Mtb with antioxidants [39]. Dectin-1 also has been
demonstrated to play a role in promoting Mtb-induced IL-
12p40 production, in which it acts to increase bacterial-host
cell interaction and thus enhance the subsequent cytokine
response in macrophages and DCs [38]. Further studies
revealed that Dectin-1 was required for proinﬂammatory
cytokine release and antimicrobial eﬀects on intracellular
mycobacterial growth in A549 cells [41].
2.3. Surfactant Protein and Mycobacteria Binding. Pul-
monary SP is a multimolecular complex comprised of
phospholipids and proteins, which are primarily secreted
by airway submucosal cells, Clara cells, and ATII cells into
to the extracellular and intra-alveolar space. There are four
main surfactant proteins that have overlapping functions,
known as SP-A, B, C, and D. Additionally, ATII cells enable
synthesis of all four SPs and surfactant lipids that are
packaged together in a unique secretory organelle known
as the lamellar body [42]. SP physiologically acts to reduce
the surface tension of the alveoli by allowing expansion of
the lung during inspiration, as well as maintaining alveolar
stability by reducing surface tension along the epithelial
lining [14, 43]. Human SPs exhibit the capacity to bind
Mtb and alter human macrophage-mediated functions in
vitro. Although, recent in vivo studies demonstrated no gross
defect in SP-A, SP-D, or SP-A/D deﬁcient mice in the uptake
or immune control of Mtb. This suggests that SP-A and
SP-D were dispensable for immune control of low doses of
Mtb challenge in vivo [44]; a number of in vitro and in vivo
studiesclearlyshowedthattheywereinvolvedinhostdefense
functions against Mtb infection [11, 14, 44, 45].
SP-A and SP-D, members of the collectin family, are
capableofinteractingwithpathogensprimarilybymediating
surfactant function [46, 47]. Previous studies have revealed4 Clinical and Developmental Immunology
the ability of SPs to regulate the initial interaction between
Mtbanditsintracellularniche,thealveolarmacrophage[48].
SP-A has been suggested to play a role in surfactant home-
ostasis and the host’s defense in the lung by its involvement
in the early capture and phagocytosis of the pathogenic Mbt
by alveolar macrophages [49]. Furthermore, SP-A has been
shown in a rat model infected with M. bovis BCG to enhance
mycobacteria killing by macrophages through a nitric-oxide-
(NO-) dependent pathway. In this study, SP-A speciﬁcally
bound to and enhanced the uptake of BCG organisms by
macrophages. The ingestion of SP-A-BCG complexes by rat
macrophages led to production of inﬂammatory mediators
and increased mycobacteria killing [50]. SP-A preferred
to bind the ligands of mannosylated lipoarabinomannan
(ManLAM) and lipomannan on the surface of BCG and
M. smegmatis, without discrimination between virulent and
nonpathogenic strains [49]. The alanine- and proline-rich
antigenic (Apa) glycoprotein, expressed with restriction in
the Mtb complex strains, was another new potential target
for human pulmonary SP-A. This glycoprotein is associated
with the Mtb cell wall for a signiﬁcant amount of time
enhancing the attachment of SP-A and possibly accounting
for the selective recognition of these strains by SP-A and
immune system c-type lectins [51].
SP-D is a lectin that recognizes carbohydrates via its
c-type carbohydrate recognition domains (CRDs), and it
has been shown to primarily bind the terminal mannosyl
oligosaccharides of Mtb to agglutinate bacilli by bridging
the carbohydrate binding domains [11]. The conformation
of SP-D is extremely important for binding to bacilli.
The 321-glutamic acid (Glu) position of human SP-D
is a critical site in the binding and regulation of Mtb-
macrophage interactions mediated by recognition of Mtb
mannosylated cell wall components [52]. The binding of
SP-D and lipoarabinomannan on the surface of Mtb may
result in bacterial agglutination, reduced uptake, and bacilli
growth impairment within human macrophages. The SP-
D-mediated inhibition of intracellular growth of Mtb in
macrophages is independent of aggregation and may be a
result of increased phagosome-lysosome fusion rather than
the generation of a respiratory burst [53, 54].
3.AirwayEpithelialCellsand
Their Host Defenses
AECs serve as the ﬁrst line of defense against pathogen
invasion by their function of structural defense as a physical
barrier and initiation and augmentation of airway host
defense mechanisms. AECs secrete numerous antimicro-
bial substances, enzymes, ROS, NO, and proinﬂammatory
chemokines and cytokines in response to invasion of a
bacterial pathogen such as Mtb, which constitutes a major
part of host defense against pathogen infections in the lung.
3.1. Antimicrobial Substances (Peptides). AECs are able to
constitutively secret and/or induce secretion of antimicro-
bial substances including lysozyme, lactoferrin, defensins,
collectins, pentraxins, secretory leukocyte protease inhibitor
(SPLI), hepcidin, and cathelicidin (LL-37). These antimi-
crobial peptides are essential elements of innate immunity.
Among them, LL-37, β-defensin 2, and hepcidin have been
demonstrated to play critical roles in innate immunity
against mycobacteria infections.
LL-37 is the only member of the cathelicidin family
identiﬁed to be expressed in human AECs and alveolar
macrophages, and it is a major antimicrobial peptide in the
innate immune system against Mtb [55]. The expression
of LL-37 has been seen in the A549 cells infected or
stimulated with mycobacteria such as BCG. BCG-mediated
upregulation was inﬂuenced by NADPH/ROS, MEK1/2,
and p38 MAPK signaling pathways, which played a central
role in the regulation of LL-37 gene expression [56, 57].
Furthermore, the induction of LL-37 expression was also
observedwithanincreasingexpressionofTLR-2,TLR-4,and
TLR-9 signaling in this epithelial cell type [56].
Human β-defensin-2 (HBD-2) is another known
inducible antimicrobial peptide associated with the
pathogenesis of human TB that has the capacity to
control the growth and chemotactic activity of Mtb
[58]. Following BCG infection, the expression of HBD-
2 in human epithelial cells was increased by means of
NF-κB modulation of increased TNF-α production. In
addition to its direct mycobicidal activity, HBD-2 also
possesses immunomodulatory functions of stimulating IL-8
production by AECs, as well as enhancing proliferation and
cytokine production of CD4+ Tc e l l .T h e s es t u d i e sp r o v i d e
insight into how epithelial-expressed HBD2 enhances the
capacity of host defense to control Mtb infection in vivo
[59].
Hepcidin (gene name hepcidin antimicrobial peptide
(HAMP)), a key negative regulator of iron metabolism in
the body, was originally identiﬁed as having antimicrobial
properties against bacterial infections. The liver is the pri-
mary hepcidin-producing organ, although other tissues such
as the lung also synthesize this antimicrobe [60, 61]. Mouse
dust cells infected with Mtb exhibit inducible expression of
hepcidin mRNA. Similarly, elevated expression of hepcidin
may be induced in human alveolar epithelial A549 cells
when stimulated by lipoglycans, particularly Mtb mannose-
capped lipoarabinomannan, and phosphatidyl-myo-inositol
mannosides. The lysed Mtb subcellular fractions and culture
ﬁltrate proteins, as well as live BCG, have been shown to
stimulate hepcidin mRNA expression in DCs [60]. These
results imply that epithelial hepcidin secretion acts as a host
defense mechanism against mycobacteria infection.
3.2. Airway Epithelial Cell Produced Proinﬂammatory Factors.
Functional PRRs expressed in epithelial cells at diﬀerent
airway mucosal sites provide the capacity of AECs to
sense the presence of pathogen infection allowing epithelial
cell secretion of various proinﬂammatory chemokines and
cytokinesagainstthepathogen.Mycobacteriaactivateseveral
signaling events upon contact with AECs that stimulate
production of tumor necrosis factor-α (TNF-α), inter-
leukins, and granulocyte-macrophage colony-stimulating
factor (GM-CSF). These proinﬂammatory factors functionClinical and Developmental Immunology 5
torecruitandactivatephagocyticcellstoeradicateorganisms
and infected cells [62–64]. Several proinﬂammatory factors
produced by AECs in response to mycobacteria infection are
listed in Table 2.
TNF-α, a cytokine involved in systemic inﬂammation
primarily secreted by the activated macrophages and lung
AECs, stimulates the acute phase reaction. Mtb was able to
penetratealveolarepitheliumbycompromisingtheepithelial
barrier properties and eliciting the production of TNF-
α after infection, which in turn reduced the bioelectric
properties of alveolar epithelium. This process may result in
establishing Mtb infection and pulmonary TB [9]. In vitro
studies on A549 cells demonstrated that Mtb-induced ROS
productionmaybeessentialforincreasedexpressionofTNF-
α, IL-6, and IL-8 in AECs. This was believed to be medi-
ated by the activation of mitogen-activated protein kinases
(MAPKs)/extracellular signal-regulated kinase (ERK) 1/2
andp38MAPKsignaling pathways[65]. Production of TNF-
α, elevating expression of IFN-γ a n di t sr e c e p t o r ,a sw e l la s
the mediator of IFN-γ signaling pathway, signal transducer
and activator of transcription 1 (STAT1) was seen in Mtb-
infected A549 cells [66].
AECs have not previously been considered as an impor-
tant source of chemokines in pulmonary TB. However,
a growing body of evidence has shown that the AECs,
particularly the alveolar epithelial cells, are a major source of
severalchemokinesecretionsinvolvedinthehostresponseto
mycobacteria infection. Furthermore, alveolar epithelial cells
may also contribute to the local inﬂammatory response in
humanTBbyproducingchemokinesthatattractmonocytes,
lymphocytes, and polymorphonuclear (PMN) cells to the
site of infection [67, 68]. IL-8 (CXCL8) is an important
activator of the host immune response to Mtb by recruiting
inﬂammatory cells to the site of infection. A signaling
pathway comprised of Duox1-TACE-TGF-α-EGFR on the
surface of AECs was suggested as a defense against BCG
infection by production of IL-8 [69]. Intracellular growth
was also necessary for mycobacteria to stimulate monocyte
chemotactic protein-1 (MCP-1, also known as C-C motif
ligand 2 (CCL2)) and IL-8 secretion by alveolar epithe-
lial cells. However, the mycobacterial virulence and rate
of intracellular growth did not correlate with chemokine
production [67]. Multiple TLRs have been shown to play
major roles in IL-8 secretion by activation of EGFR via
cell signaling cascades in AECs [37, 70, 71]. Production
of IL-8 in BCG-infected human epithelial cells could be
reduced by IL4, another important cytokine in human TB.
H o w e v e r ,I L - 1 0p r o d u c t i o nw a su n a l t e r e db yI L - 4i nt h e
AECs [72]. The expression of IL-10 was induced by IL-27
in bronchial epithelial cells regulated by the activation of
the phosphatidylinositol 3-OH kinase (PI3K)-Akt signaling
pathway [73]. Function of IL-27 was related to the pathogen-
esis of chronic obstructive pulmonary disease (COPD) and
patients with pulmonary TB.
IL-18 is a member of the IL-1 cytokine superfamily and
is secreted by macrophages and other cell types including
human ATII cells. IL-18 plays an important role in the
induction of a cell-mediated immunity by binding to its
receptor following infection [74] .H u m a nA T I Ic e l l sa r ea
Table 2: Epithelial cell produced chemokines and cytokines against
mycobacteria infections.
Inﬂammatory factor Producing cells Reference
TNF-α Alveolar epithelial cells [9, 65]
IFN-γ Alveolar epithelial cells [66]
GM-CSF Bronchial epithelial cells [105]
IL-1 Airway epithelial cells [76]
IL-4 Human bronchial epithelial
cells [72]
IL-6 Alveolar epithelial cells [65]
IL-8 (CXCL8) Airway epithelial cells,
alveolar epithelial cells [65, 66, 76]
IL-10 Bronchial epithelial cells [73]
IL-18 Human alveolar type II cells [74, 75]
IL-27 Bronchial epithelial cells [73]
IP-10 Alveolar epithelial cells,
bronchial epithelial cells [67, 76–78]
MIG Bronchoepithelial cells [78]
I-TAC Bronchoepithelial cells [78]
MCP-1 Alveolar epithelial cells [67, 76, 77]
IP-10: interferon-inducible protein-10; MIG: monokine induced by IFN-
gamma; I-TAC: IFN-inducible T-cell alpha-chemoattractant; MCP-1:
monocyte chemoattractant protein-1.
major resource of IL-18, and a baseline of IL-18 expression
could be detected in normal ATII cells. The ATII cells
and ATII-derived IL-18 might play a potential role in the
pathomechanism of granulomatous in pulmonary TB. This
is supported by the previous ﬁndings that ATII cells produce
IL-18 in primary lung tissue cultures from patients with
pulmonary TB [75]. This study found markedly increased
IL-18 mRNA levels and increasing amounts of intracellular
IL-18 protein with increasing culture time in ATII cell
cultures stimulated with Mtb whole cell lysate. Additionally,
the expression and secretion of mature IL-18 protein from
human ATII cells was altered by the proinﬂammatory
cytokines TNF-α,I L - 1 β,a n dI F N - γ [75].
Other inﬂammatory factors found to be produced
in mycobacteria infected airway epithelial cells include
granulocyte colony-stimulating factor (G-CSF), GM-
CSF, interferon-inducible protein-10 (IP-10, also known
as C-X-C-motif chemokine 10 (CXCL10), secreted by
cells in response to IFN-γ), IFN-γ-inducible T-cell α-
chemoattractant (I-TAC, also called CXCL11 or IP-9,
a small chemokine chemotactic for activated T cells),
monokine induced by IFN-γ (MIG, also known as CXCL9,
a T-cell chemoattractant induced by IFN-γ), monocyte
chemoattractant protein-1 (MCP-1), and leukotriene B4.
The epithelial cells also produced inﬂammatory factors that
play important roles in the recruitment of activated T cells
and pathogenesis of pulmonary diseases in which IFN-γ is
highly expressed, such as pulmonary TB [67, 76–78].
3.3. Alveolar Epithelial Cell Necrosis and Mycobacterial Infec-
tion. Mycobacteria are able to invade and replicate in both6 Clinical and Developmental Immunology
macrophages and epithelial cells in the alveolar spaces of
the lung. The alveolar epithelial cells actively contribute
to the innate immune response in the lung and play an
important role in mycobacterial dissemination during pri-
mary infection by undergoing cellular necrosis and releasing
mycobacteria. Though the mycobacteria infection induces
alveolar epithelial cell apoptosis, necrosis is the primary
cause of cell death in infected alveolar cells. The necrosis
was not a consequence of mycobacterial growth or the
production of inﬂammatory factors in the host cells, but
due to increased permeation of the cell membrane and the
infection of live bacilli [79, 80]. The suppressed apoptosis
in the infected alveolar cells correlated with an upregulation
of apoptosis inhibitors bcl-2 and Rb, and a downregulation
of proapoptotic genes, BAD and BAX. This ﬁnding was
opposite to that in mycobacteria-infected macrophages,
suggesting that diﬀerential induction of apoptosis between
macrophages and alveolar epithelial cells exists representing
cell-speciﬁc strategies used by Mtb for survival in the host
[80].
3.4. Epithelial Cells Secreted Matrix Metalloproteases and
TB Immunopathology. The mechanism of Mtb lung tissue
damage and mycobacterial spread remains poorly under-
stood. Previous studies demonstrate that matrix metallo-
proteases (MMPs) have a unique ability to degrade ﬁbrillar
collagen at neutral pH leading to lung matrix destruction
[81–85]. MMP activity was dependent upon a monocyte-
epithelial cell network and p38 MAPK phosphorylation to
achieve the matrix-degrading phenotype [83]. The Mtb
6kD early secreted antigenic target (ESAT-6) protein was
able to induce MMP-9 secretion from the epithelial cells
neighboring infected macrophages [86]. Human primary
bronchial epithelial cells cultured with conditioned medium
from Mtb-infected monocytes (CoMTb) had upregulated
levels of MMP-1. This increasing of MMP-1 was mediated
via phosphorylation of p38 MAPK that was induced by
synergism of CoMTb-driving TNF-β and G protein-coupled
receptor activation, and the decreasing of tissue inhibitor
of metalloproteinase 1 (TIMP-1) secretion. Clinically it has
been shown that activated p38 localized to the MMP-1-
secreting AECs of TB patients [81]. Furthermore, CoMTb
w a sa b l et ou p r e g u l a t eM M P - 9g e n ee x p r e s s i o na n ds e c r e t i o n
in primary human bronchial epithelial cells, while inhibition
of the p38 MAPK activity led to decreased secretion of
MMP-9. TNF-α was necessary, but not suﬃcient for MMP-
9 upregulation by a monocyte-epithelial cell network. This
suggests that undeﬁned soluble factors in CoMTb may
synergize with TNF-α to increase MMP-9 secretion in the
epithelial cells [82]. These results clearly imply that host-
a n dp a t h o g e n - d e r i v e df a c t o r sm a yw o r ki nc o n c e r tt oM t b
infection to drive MAPK-dependent MMPs secretion from
AECs. Increased MMP secretion may lead to enhanced
recruitment of macrophages, which contributed to earlier
granuloma maturation and bacterial growth. This notion
was supported by the fact that disruption of MMP9 function
alleviated granuloma formation and bacterial growth [87].
Hence, interruption of the production of epithelial MMPs
may be a therapeutic target for treatment of TB.
3.5. Airway Epithelial Cells Produce Nitric Oxide against
Mycobacteria Infection. Nitric oxide (NO) and reactive oxy-
gen intermediates are toxic molecules used by the immune
system. Production of NO by host cells is an eﬀective host
defense mechanism against microbial infection. Bose et al.
demonstrated that in a murine TB model NO production
played an essential role in Mtb killing by mononuclear
phagocytes, particularly during the early phase of the
infection. Additionally, it may also play a role in tissue
damage during the late phases of the disease [88]. In
vitro studies using A549 cells showed an induction of NO
in response to Mtb infection, which is consistent with
the ﬁnding that NO has antimicrobial eﬀects against Mtb
infection [89]. These results suggest that a correlation exists
between NO production and innate immunity of AECs
against mycobacteria [90].
4. AirwayEpithelialCells: The Connection of
InnateandAdaptiveImmunity
Airway epithelial cells have been recognized to play impor-
tant roles in the defense of invaded microbial pathogens,
via both the innate and adaptive immune responses [2,
4]. It has become increasingly evident that AECs express
PRRs that recognize microbial pathogens and activate innate
host defense mechanisms in the airway. Furthermore, the
activated innate response secondarily induces recruitment
and activation of DCs, T cells, and B cells that augment anti-
gen recognition, antibody production, and other adaptive
immune components. These response mechanisms include
epithelial production of cytokines and chemokines that
stimulate communication between the “nonprofessional”
(epithelial cells) and “professional” (B cells, T cells, DCs, and
macrophages) immune cells [4].
Following infection of mycobacteria, the host immune
system must ﬁrst recognize the invading pathogens, activate
the innate response, and initiate the adaptive immune
response. Though “professional” immune cells play a central
role in the initiation of adaptive immunity, the alveolar
epithelial cells are among the ﬁrst cell types to encounter
mycobacterial pathogens, implying that crosstalk between
alveolar epithelial cells and “professional” immune cells
may be important in initiating a coordinated secretion of
chemokines and the subsequent recruitment of leukocytes
to the lung. ATII cells are capable of producing various
antimicrobial and proinﬂammatory molecules that con-
tribute to pulmonary immunity. These cells do so not only
by secreting chemokines that recruit inﬂammatory cells to
the lung but also serving as antigen-presenting cells [91].
Although ATII cells are unlikely to prime na¨ ıve T cells,
their ability to present antigens to T cells suggest that
they may play a role in the eﬀector phase of the immune
response [91]. Interestingly, the migration of monocytes
across the alveolar epithelial-endothelial barrier required
the production of chemokines and the presence of surface
moleculesonboththealveolarepithelialandendothelialcells
[10]. These studies demonstrate a novel role for ATII cells in
the immunological response to pulmonary pathogens suchClinical and Developmental Immunology 7
as Mtb [91]. However, the interaction between AECs and
immune cells (e.g., the macrophages) in response to Mtb
infection is currently largely unknown.
5. Concluding Remarks
It is well accepted that airway epithelium plays an important
role in the innate immune response by its collection of
surface, endosomal, and cytosolic sensors that activate
numerous proinﬂammatory signal pathways. Additionally,
resident antimicrobial substances secreted by the epithelial
cells oﬀer signiﬁcant mechanisms to deal with the invaded
pathogens.Agrowingbodyofevidencesupportstheessential
involvement of AECs in both the innate and adaptive
immune responses against mycobacterial infection. These
studies have facilitated the understanding of the major
components of the innate immune system and their role
in the host’s defense of AECs, despite the fact that the
interaction between AECs and Mtb is far less known in
comparison with the interplay of alveolar macrophages and
this pathogen. A recent study using Mycobacterium marinum
in the zebra ﬁsh model revealed a molecular mechanism of
mycobacteriainducegranulomas,ahallmarkoftuberculosis.
In this mechanism model, the mycobacteria secreted ESAT-
6 induced MMP-9 in those epithelial cells neighboring the
infected macrophages, which in turn contributed to nascent
granuloma maturation and bacterial growth by increasing
the recruitment of macrophages to sites of infection [86, 87].
Together with the ﬁndings of the ability of epithelial cell-
secreted SPs to regulate the initial interaction between Mtb
and alveolar macrophage, these studies provide an insight
intotheinteraction/crosstalkbetweenmacrophagesandAEC
in pathogenesis of TB [48, 49, 86, 87].
AECs act to sense infectious danger by functionally
expressing PRRs. Meanwhile, they are able to limit poten-
tially harmful inﬂammatory reactions within the framework
of organ-speciﬁc immunity by increasing the activation
threshold [92]. In the case of mycobacterial infection,
interaction between the pathogen and AECs results in
the production of antimicrobial substances or peptides,
lysozyme, lactoferrin, β-defensins, and NO. Furthermore,
these cells produce and secrete proinﬂammatory cytokines
and chemokines thus initiating the adaptive response by
recruitment of inﬂammatory cells. The mechanisms used by
the airway epithelium to discriminate between pathogenic or
nonpathogenic Mycobacterium, sense pathogens to immune
eﬀectors, interaction/crosstalk between AECs and alveolar
macrophages, as well as the clinical relevance of epithelial
cell-mediated immune responses, have yet to be fully eluci-
dated.
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